SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QDEL - Quidel more quick diagnosis
QDEL 27.52-2.2%Nov 26 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jad who wrote (354)1/23/1997 9:34:00 AM
From: Robert Busse   of 1693
 
Joe + Mike,

This eps report exceeded my optimistic estimates- if the market doesn't respond to these numbers, it may take dynamite to move it- if the market is stupid enough to ignore this report, I suggest we start buying more -eventually they will notice-you can't have 30% revenue growth and 328% net profit growth for long before someone notices- remember, these numbers do not include any of the benefits of the P+G agreement, which is not set to start tll 2-1-97- that deal may cost QDEL a few bucks ($200,000?? 43,000 drs offices + clinics x 2 free samples x the cost of producing each test for QDEL = ??$200,000 or so), but that deal will ultimately be a fantastic marketing coup for QDEL- I think the costs of this deal will largely be absorbed during the 4th quarter, but it will make H. pylori a big seller throughout the year and make QDEL's earnings and revenue somewhat less seasonal- thank goodness H.pylori is a "year round" disease! I look for eps of at least $0.05 in the 4th quarter and possibly as high as $0.08 again if the strep a "pipeline" wasn't completely filled in the 3rd quarter and/or the strep a season is bad (good for QDEL?). That would put the yearly earnings at the high end of estimates at 15 to 18 cents. Even at a relatively conservative p/e multiple of 40 x these actual fy 97 earnings, it would put QDEL at 6 (40 x .15) to 7.2 (40 x .18)per share. I think a 40 multiple is rather conservative for a company with this type of growth potential. A p/e of 50 time these 15 to 18 cents annual levels yields a price of 7.50 to 9 per share. If fy 98 estimates are in the area of $0.25 (very doable in my opinion- approx 6-7 cents per share per quarter), a 40 p/e yields a price of $10/share and a 50 p/e gives us a price of 12.5. Please forgive me for my optimistic ramblings but these numbers are not at all unreasonable- we now see that any increase in sales really does go pretty much straight to the bottom line. NONE OF THIS INCLUDES P+G DEAL, GLAXO DEAL, BAYER DEAL, OR SAFEPLAN. tHIS STOCK IS A LONG TERM HOLD IN MY OPINION,although I will be sorely tempted to sell a few shares if it hits 10- We all need to be patient since I think we will look back ata price of 10 and laugh 2 years from now when the stock is at 15+. BOB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext